Prognostıc Factors In Testıcular Cancer
Open Access
- 27 May 2024
- journal article
- research article
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
Abstract
Aim: Testicular cancer is the most common cancer in men aged 15-35 years and accounts for 1% of all lifetime male cancers. There are two histologic subtypes: seminoma and nonseminoma. In our study, we aimed to investigate the factors predicting recurrence in early-stage testicular cancer. Materials and Methods: Our study is a retrospective study of early stage testicular cancer admitted to the medical oncololi clinic of our hospital between 2006-2018. During the study, 344 patient files were reviewed and 130 patients who met the study criteria were included in the study. Our primary aim in this study was to investigate the factors predictive of recurrence in early stage testicular cancer. Results: When evaluating PFS in patients with nonseminoma with and without lymphovascular invasion, no median PFS value was reached in either group. However, PFS was worse in patients with LVI (p=0.037). When comparing stage 1 with stage 2 seminoma patients, no median PFS values could be reached, but there was a statistical difference between the two groups in terms of recurrence (p=0.019). Conclusions: In our study, we found no association between tumor size, embryonal carcinoma predominance, tunica albuginea invasion, spermatic cord involvement and tumor marker values and recurrence in nonseminoma germ cell testicular tumors. PFS was shorter in patients with LVI compared to those without LVI. Lymphovascular invasion, spermatic cord involvement, tunica albuginea involvement, and rete testis involvement were not associated with disease recurrence in seminoma patients, whereas higher disease stage predicted the risk of recurrence.Keywords
Funding Information
- YOK
This publication has 20 references indexed in Scilit:
- Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)Annals of Oncology, 2016
- Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)Annals of Oncology, 2014
- Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s ExperienceEuropean Urology, 2011
- Current management of stage I testicular non-seminomatous germ cell tumoursCritical Reviews in Oncology/Hematology, 2009
- Medical Treatment of Advanced Testicular CancerJAMA, 2008
- A comprehensive systematic review of testicular germ cell tumor surveillanceCritical Reviews in Oncology/Hematology, 2007
- Recurrence in Nonseminomatous Germ Cell Testis Tumor Patients with No Viable Tumor at Postchemotherapy Retroperitoneal Lymph Node DissectionUrology, 2007
- Management of patients with low-stage nonseminomatous germ cell testicular cancerCurrent Treatment Options in Oncology, 2005
- A RATIONAL APPROACH TO MANAGING STAGE I NONSEMINOMATOUS GERM CELL CANCERUrologic Clinics of North America, 1998
- Primary Retroperitoneal Lymph Node Dissection in Clinical Stage A Non‐seminomatous Germ Cell Testis Cancer Review of the Indiana University Experience 1965–1989British Journal of Urology, 1993